Equity
€4.2m ▲ 139%
Equity rose in 2025: restructuring with BMEDI.
BOFAR
Lifetime
19 annual accounts with figures on one time axis, 41 filings since 1985peak €2.0m (2023)
-not published
peak €2.6m (2024)
€2.1m▼ 20.0%
peak €4.2m (2025)
€4.2m▲ 139%
€7.9m▲ 57.9%
peak 8.6 FTE (2022)
6.3 FTE▼ 17.1%
Board7 names since 2014
-
Owners3 names in the annual accounts
100% and 1 other
Documentsfilings and deeds
20-07-202611 days before the deadline
2025financial year
Staff from 7.6 FTE to 6.3 FTEMerger proposal: BOFAR takes over BMEDI 24-111 statutory auditor reappointed 10-10New managing director 29-08Equity from €1.8m to €4.2mDebts from €5.0m to €7.9m
Key points
from the 2025 annual accountsInvestments
€148,918 2.4 × depreciation
Green is investment, beige is depreciation. Machinery stands 33.6% higher than in 2024.
Staff
6.3 FTE from 8.6 in 2022
Between 2022 and 2025, 27% of the full-time equivalents disappeared.
Liquidity
2.99 was 1.51 in 2024
Short-term debts fell from €4.3m to €3.9m.
Filings
41 annual accounts since 1985
Eight of the last ten came late. The 2019 accounts came latest: 103 days after the end of the period.
Board
3 left
Directors left. Latest change 30-12-2025 · 0 in office.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,386 companies had the same profile as BOFAR has now. Each dot stands for 79 companies, two years later.
93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,386 companies, not a prediction for BOFAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
last known boardDirector, until 2025
Managing director, until 2025
Director, until 2025
Director, until 2025
Auditor,
- 100%equity €979,732 (2025) · annual accounts 2025
Recent changes
Permanent representatives: and
Board meeting of 07-10-2026 · Gazette deed
Merger: BOFAR takes over BMEDI
46 new shares · Appointment: (statutory auditor) · Resignations: (managing director), and · General meeting of 30-12-2025 · Gazette deed
Merger proposal: BOFAR takes over BMEDI
Gazette deed
1 statutory auditor reappointed
Permanent representatives: and · (statutory auditor) · General meeting of 27-06-2025 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BOFAR Wingene | €23.9m | 10.7% | 34.8% | 6.3 |
| ORMCO BELGIQUE Mechelen | €20.5m | 4.5% | 31.3% | 5.7 |
| MEDISALE Ghent | €32.9m | 0.9% | 24.8% | 8.3 |
| VETRIA Beernem | €16.1m | -1.1% | 44.2% | 4.7 |
| Lundbeck Ixelles | €23.4m | 3.8% | 65.6% | 10.7 |
| IBIS PHARMA Schaerbeek | €16.9m | 4.6% | 67.1% | 5.8 |
| BAUSCH & LOMB PHARMA Wavre | €37.4m | 3.1% | 8.2% | 11.6 |
Grey: the largest companies of the sector (wholesale trade (NACE 46)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as BOFAR: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €5.2m and €14m, founded between 1968 and 1992.
Official details
Source: KBO- Status
- Active since 20-06-1984Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460and 1 other
- Joint committee
- 321Wholesale distributors of medicines · annual accounts 2025
- Establishment unit
- 2.024.984.6688750 Wingene, since 20-06-1984
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- €12.2m▲ 78.9%
- Employeeson 31-12-2025
- 6▼ 25.0%
- Filing
- Filed on 20-07-2026, 11 days before the end of the filing period
Insights on BOFAR
BOFAR has existed since 1984. The gross margin fell from €1.6m in 2007 to €287,093 in 2008.
Solvency rose in 2025 from 26.1% to 34.8% because of the retained profit and a capital increase.
holds all the shares. In December 2025, three directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BOFAR
- What is the company number of BOFAR?
- The company number of BOFAR is 0425.935.908. The VAT number is the same number with BE in front: BE 0425.935.908.
- Where is BOFAR based?
- The registered office is at Flandria 3, 8750 Wingene.Company details
- What does BOFAR do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of BOFAR?
- BOFAR is a public limited company (NV).
- When was BOFAR founded?
- BOFAR was founded on 20-06-1984.
- Is BOFAR still active?
- Yes, BOFAR is an active enterprise in the KBO register.
- How many employees does BOFAR have?
- BOFAR had an average of 6.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does BOFAR fall under?
- In its 2025 annual accounts, BOFAR states joint committee 321 (Wholesale distributors of medicines).
- What is the turnover of BOFAR?
- The turnover of BOFAR was €23.9m in financial year 2025, according to the filed annual accounts.
- Is BOFAR profitable?
- In financial year 2025, BOFAR made a profit of €2.1m.
- Where can I find the annual accounts of BOFAR?
- BOFAR filed 41 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BOFAR due?
- BOFAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.